Funding round · 2026-11-11 · Healthcare
VectorY Therapeutics raises $80.5M
68
AI Score
Amount
$80.5M
Round
Undisclosed
Lead
Not disclosed
HQ
Amsterdam, NL
Why it matters: The round shows which investors are backing AAV-delivered antibody therapies for ALS and Huntington's, and where the lead program stands in its Phase 1/2 trial.
VectorY Therapeutics, an Amsterdam biotech, raised €74.5M ($83.5M) from new investors including Angelini Ventures.
- Participants:
- Angelini Ventures, Invest-NL, European Investment Bank, Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, ALS Investment Fund
- Source:
- EU-Startups Funding ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for VectorY Therapeutics
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing